翻訳と辞書 |
N-Acetylprocainamide : ウィキペディア英語版 | N-Acetylprocainamide
''N''-Acetylprocainamide (NAPA or acecainide) is the ''N''-acetylated metabolite of procainamide. It is a Class III antiarrhythmic agent, whereas procainamide is a Class Ia antiarrhythmic drug. It is only partially as active as procainamide; when checking levels both must be included in the final calculation. ==History== In the early 1930s, Claude Beck was undertaking pioneer cardiac surgery at the Lakeside Hospital in Cleveland, Ohio. During and after his surgery he was facing problems with arrhythmias, these problems were investigated experimentally by Frederick R Mautz. For this experiments he used drugs that are similar to cocaine, because these drugs were readily absorbed from mucous membranes and were also known to have some effect on the myocardium. Mautz used procaine but its action was short-lived owing to esterase action. From procaine Mautz synthesized procainamide which has no esterase action. Also procainamide has the advantages of being enzyme resistant and active by mouth. Procainamide was approved by the US FDA on June 2 1950 under the brand name Pronestyl. In 1951 Pronestyl was launched by Bristol-Myers Squibb, a pharmaceutical company in the US. Along with the discovery of procainamide came the discovery of its metabolite ''N''-acetylprocainamide.
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「N-Acetylprocainamide」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|